[ILS-SA-40] Lunch Seminar 40: Recent managements of retinitis pigmentosa
- Apr 05 (Sat)
- 12:15 - 13:15
- Room 9 - Tokyo International Forum 6F G602
- R-Tech Ueno, Ltd
- Retina, Vitreous body
- Chair）Yozo Miyake
- Epidemiologic researches of RP patients with mid to late stages are necessary to develop appropriate clinical endpoints for coming new treatments. Although visual acuity is the most common clinical endpoint, it takes long time to show the prevention of loss of vision in the clinical trial through new therapies. To develop the new therapies for RP, clinician scientists who are familiar with not only basic and clinical researches but also applied research will play important roles. In this seminar, three clinician scientists will present the managements of recent RP treatments: clinical endpoints for RP study, gene therapy, and iPS cell therapy.